The US health regulator has made observations in its Establishment Inspection Report (EIR) for Wockhardt’s three units in Maharashtra and ban on exports from the facilities to the US will continue. The company’s three facilities - Chikalthana and two units at Waluj in Maharashtra - have received EIR with observations. EIR is given to an establishment after the completion of the inspection by the US Food and Drug Administration (USFDA).
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
